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Three-dimensional (3D) spheroidal cell cultures are now recognised as better models of cancers as 
compared to traditional cell cultures. However, established 3D cell culturing protocols and techniques 
are time-consuming, manually laborious and often expensive due to the excessive consumption of 
reagents. Microfluidics allows for traditional laboratory-based biological experiments to be scaled 
down into miniature custom fabricated devices, where cost-effective experiments can be performed 
through the manipulation and flow of small volumes of fluid. In this study, we characterise a 3D cell 
culturing microfluidic device fabricated from a 3D printed master. HT29 cells were seeded into the 
device and 3D spheroids were generated and cultured through the perfusion of cell media. Spheroids 
were treated with 5-Fluorouracil for five days through continuous perfusion and cell viability was 
analysed on-chip at different time points using fluorescence microscopy and Lactate dehydrogenase 
(LDH) assay on the supernatant. Increasing cell death was observed in the HT29 spheroids over the 
five-day period. The 3D cell culturing microfluidic device described in this study, permits on-chip 
anti-cancer treatment and viability analysis, and forms the basis of an effective platform for the high-
throughput screening of anti-cancer drugs in 3D tumour spheroids.
The interest in and practicality of microfluidic systems for biochemical analysis of living cells and tissues has 
dramatically increased over the past  decade1,2. ‘Lab-on-a-chip’ technologies carry many advantages, including the 
convenience of culturing cells and performing analytical techniques on small microfabricated platforms. Con-
sequently, these devices consume only a fraction of the amount of reagents, tissue culturing media and precious 
biological specimens as do conventional in vitro experiments that are carried out in large commercial plates and 
 flasks3. Another advantage of microfluidic devices for biomedical research is their ability to streamline complex 
assay  protocols4. For instance, fluid flow enables the culture and treatment of cells to be spatially and temporally 
controlled with a great degree of  accuracy5. Specifically for anti-cancer research, microfluidic systems have the 
potential to quickly and easily screen drugs in real time and diagnose  disease6.
Concurrent with the increasing practical application of microfluidics in the biomedical sciences, three-dimen-
sional (3D) cell culturing is increasingly being adopted in anti-cancer research, especially for the purpose of drug 
development. In comparison to conventional two-dimensional (2D) monolayer cell cultures, 3D spheroids are 
recognised as better in vitro models of cancer due their inherent properties, making them more comparable to 
tumour in vivo7. Cells in 2D cultures are uniform in their rate of proliferation, access to oxygen and nutrients 
and response to treatment, whereas the architectural arrangement of cells in 3D spheroids, together with the 
physiological gradients of oxygen, nutrients, growth factors and catabolites results in the uneven growth and 
diverse survival rates of cells. In addition, the layered structure of cells influences the ability of anti-cancer 
therapeutics to penetrate through and induce cytotoxicity in the different regions of the spheroid. Cells cultured 
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in a 3D structure also experience different mechanical and topographical forces, than those growing on a 2D 
planar  surface8. The overall benefit of 3D spheroidal models is that they offer a better understanding of in vivo 
molecular mechanisms involved in tumour growth and drug  resistance9.
Taken together, 3D spheroids offer a better representation of in vivo environments and microfluidic devices 
offer convenient and cost-effective platforms for high-throughput screening applications. A common limitation 
among established 3D cell culturing techniques is the manual effort required to grow and maintain 3D spheroid 
cultures in non-specialised conventional commercial tissue culturing equipment. An appropriately designed 
microfluidic platform can improve the success rate of establishing and characterising 3D spheroids by reducing 
the amount of effort required for cell culturing, administering cytotoxic treatments and evaluating the outcomes 
of treatment—conveniently within a single  device5,10–16.
In this article, we describe the development and application of a 3D cell culturing microfluidic flow platform 
and the use of 3D printing to create a master from which polydimethylsiloxane (PDMS) flow chips can be 
conveniently cast. We demonstrate the platform by culturing 3D spheroids, treating with the anti-cancer drug, 
5-Fluorouracil (5-FU) and evaluating cytotoxicity through flow. We show that the 3D cell culturing microfluidic 
platform we have developed can accommodate the generation of 3D spheroids from cell aggregates ‘on-chip’, 
administer cytotoxic treatment under limited- and continuous perfusion conditions and perform quantitative 
and qualitative cell viability analysis.
Results
The microfluidic device described in this study utilises the non-cell adherent properties of the PDMS flow chip 
located between two layers of Poly(methyl methacrylate) (PMMA), to generate 3D spheroids (Fig. 1A)17. Plac-
ing a cell seeding port directly above the cell culturing wells was vital to improving the efficiency of introducing 
cells to the wells. The port was added after it was identified that perfusing a HT29 cell suspension through the 
device to seed the wells was not effective (Fig. 2A,B). Seeding cells through direct deposition via the cell seeding 
port, results in 3D spheroids forming in 100% of the wells, as compared to 68% using flow-driven cell seeding 
(p = 0.02) (Fig. 2C). An equivalent number of HT29 cells, (mean = 377 cells, min. = 361 cells, max. = 386 cells), 
were deposited into each well to generate 3D spheroids (Fig. 2D). The central region of the PDMS flow chip was 
designed with a 5 × 5 array of concave-shaped spheroid culturing wells (Fig. 1B). The concave-shaped wells were 
designed to aid in the cell seeding process, by assisting cells in initially forming cell aggregates, which is vital for 
successfully generating 3D spheroids (Fig. 3).
As depicted in Fig. 4A, after seeding the HT29 cells into the wells of the PDMS flow chip, cell aggregates 
formed within a day (Day 0) and subsequent culturing under static conditions, resulted in 3D spheroids form-
ing by Day 2. The HT29 spheroids then continued to mature in density, roundness in spheroidal structures and 
grew in overall size. A 148% (p < 0.0001), 89% (p < 0.0001) and 58% (p < 0.0001) increase in spheroid volumes 
were found between Day 2 versus Day 4, Day 4 versus Day 7 and Day 7 versus Day 10 respectively (Fig. 4B). 
Following 10 days of culture, scanning electron microscopy confirmed the spheroidal structures of the HT29 
spheroids (Fig. 4C).
Using the microfluidic platform, further experiments were carried out to highlight the (1) administration 
of an anti-cancer drug to 3D HT29 spheroids and (2) evaluate cytotoxicity induced by the anti-cancer drug 
through the microfluidic device. For limited-perfusion experiments, a single syringe pump was connected to 
the microfluidic devices and was used to drive flow (Fig. 5A,B). Briefly, 3D HT29 spheroids were generated on 
chip and subjected to 5-FU treatment (500 µM) through perfusion. After 24 h under non-flow static conditions, 
cell viability analysis showed that 5-FU treated HT29 spheroids were 70% less viable, as compared to untreated 
spheroids (p = 0.0001) (Fig. 5C). Fluorescent imaging highlighting cell death confirmed cytotoxicity in 5-FU 
treated spheroids, as indicated by the uptake of propidium iodide and lack of dye uptake in untreated HT29 
spheroids (Fig. 5D). Quantifying propidium iodide fluorescence also confirmed cytotoxicity in 5-FU treated 
spheroids with no toxicity detected in untreated spheroids (p < 0.0001) (Fig. 5E). In addition, a 20% reduction 
in Hoechst 33342 fluorescence in treated spheroids, as compared to untreated spheroids (p = 0.028) indicated 
the loss and shedding of cells following 5-FU treatment (Fig. 5E).
Microfluidic device-cultured HT29 spheroids were also subjected to 5-FU treatment (200 µM) through 
continuous perfusion. The microfluidic devices were connected in parallel to reagent-loaded syringes through 
a peristaltic pump (Fig. 6A,B). Cell viability was monitored over 5 days and a time dependant reduction in cell 
viability was observed (p < 0.0001) (Day 0 = 100% cell viability and Day 5 = 15% cell viability, p < 0.0001) (Fig. 6C). 
Fluorescent imaging confirmed results of the LDH assay, as indicated by the increasing uptake of propidium 
iodide over time (Fig. 6D). In addition, quantifying propidium iodide fluorescence also showed significant cyto-
toxicity over the 5 days (Day 0 vs. Day 5: p < 0.0001) (Fig. 6E). A 16% reduction in Hoechst 33342 fluorescence 
was also observed at Day 5, as compared to Day 0, indication the loss and shedding of cells (p = 0.0003) (Fig. 6E).
Discussion
Three-dimensional in vitro spheroidal models of cancer are recognised as more accurate representations of the 
tumour microenvironment as compared to 2D monolayers, and responses to treatment in 3D cultured cells are 
more reflective of responses observed in vivo8. Combined microfluidics and 3D spheroid culturing has allowed 
conventional laborious 3D cell culturing protocols to be scaled down onto custom micro-fabricated devices. This 
allows the generation, culturing, treatment and analysis of 3D spheroids to be performed conveniently on-chip 
through fluid  perfusion18–23, with the additional practical advantages of reduced experimental and consumables 
costs and reduced manual  labour23.
The 3D cell culturing microfluidic device described in this paper, builds upon previous work and is based 
upon the ‘non-cell adherent’ technique for generating 3D  spheroids10,24–27. Cells are seeded on a non-adherent 
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Figure 1.  Designing the microfluidic device. The PDMS 3D cell culturing microfluidic device consisted of a central 3D cell 
culturing PDMS chip and is sandwiched in between two layers of PMMA. The inverse design of the PDMS chips was printed 
as a reusable master mould in a photocurable acrylonitrile butadiene styrene thermoplastic polymer. The PMMA layers were 
machined from cast sheet, with inlet and outlet ports positioned to match the ends of the PDMS chip and machined to take 
standard UNF 1/4-28 flangeless fittings for the two ports for flowing fluids through the device. The device was held together 
using four bolts with one in each corner. (A) Photographic image of the microfluidic device with a blue dye flowing through 
device and over the 3D spheroid culturing wells. Scalebar = 1 cm. (B) Transillumination microscopic image of the 3D cell 
culturing wells in the center of PDMS chip which could accommodate the simultaneous culturing of twenty-five 3D spheroids 
in a 5 × 5 array. Scalebar = 500 μm.
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substrate, preventing them from adhering to the surface and instead forming cell  aggregates26. The PDMS flow 
chip used for our microfluidic device is a non-cell adherent substrate, biocompatible, facilitates the exchange of 
gases and has been used extensively for fabricating 3D cell culturing microfluidic  platforms5,11,12,14–16,18–21,27–41. 
Figure 2.  The efficiency in seeding cells and generating 3D spheroids between the addition of cells through 
the seeding port and perfusing cells through the microfluidic device. Transillumination images of HT29 cells in 
suspension that were (A) added directly through the top cell seeding port and (B) seeded through fluid flow into 
the microfluidic device. For both conditions, the microfluidic devices were kept under static conditions for 48 h 
to allow 3D HT29 spheroids to form. This demonstrates the importance of seeding cells directly to the location 
of the wells rather than through flow. Images are representative of at least 3 independent experiments. (C) 
Seeding cells directly into the wells is more effective at successfully culturing 3D spheroids in all the wells of the 
microfluidic device as compared to seeding cells through flow (3 replicates per experiment). (D) 20 μL of HT29 
cells (2 × 107cells/mL) were seeded through the top mounted cell seeding port using a pipette. 5 wells from each 
5 × 5 array of wells were randomly selected and the number of cells seeded into the wells were manually counted 
(5 wells/replicates per experiment). Data shown represent means with standard deviation of 3 independent 
experiments for both spheroid counting and cell counting experiments.
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SU-8 based microfluidic platforms are also commonly used for 3D cell culturing systems, however the chemical 
treatment of SU-8 to produce hydrophobic surfaces requires dangerous and toxic chemicals to be  used42. We 
employed 3D printing and PDMS casting, which does not require surface treatment or bonding to other materi-
als, making the fabrication of the flow chips inherently simple. The flow chips were cast from a mould designed 
with concave-shaped spheroid-culturing wells to facilitate the aggregation of cells and assist in the generation 
of 3D spheroids, as has been described previously for 3D cell culturing  platforms43,44. Due to the nature of the 
photocuring method for forming the 3D prints, the master mould is built in layers forming ‘steps-like’ structures 
as an approximation to the convex well to make the 3D cell culturing wells (Fig. 7). These structures were never-
theless still successful in generating spheroids in the polygonal concave-shaped wells. Our method for making 
3D spheroid culturing chips is effective, yet simple enough to allow biologists and non-microfluidics specialists 
to produce and operate these chips in their laboratories without the need of a cleanroom or delicate microfab-
rication/assembly steps. The PDMS-based spheroid culturing chip was designed to accommodate the culture of 
twenty-five spheroids (Fig. 1B). As a prototype design, we limited culturing to twenty-five spheroids, yet retain 
reliability and simplicity in generating 3D spheroids, as compared to conventional 96-well plates. However, 
the advantage of our design is such that the 5 × 5 array of spheroid-culturing wells, could easily be expanded to 
accommodate the simultaneous culturing of larger numbers of 3D spheroids.
A limitation of previously reported 3D cell culturing microfluidic platforms is that they have relied on external 
3D cell culturing methods, such as the use of ultra-low attachment plates or the hanging drop method, to generate 
spheroids off-chip before being introduced into the microfluidic  platforms5,13,35,36,40. The microfluidic platform 
described in this study eliminates the need for generating 3D spheroids beforehand and allows non-aggregated 
cells to be seeded directly into the device, with equivalent numbers of cells seeded into each well (Fig. 2D). We 
found the seeding of cells through flow, to be inefficient in generating spheroids. For biomedical applications, 
the use of a pipette to seed cells in an exact location on a microfluidic chip is an advantage when accurately pro-
ducing spheroids. This user-friendly approach is also compatible in conventional biology laboratories. For our 
experiments, the human colorectal adenocarcinoma cell line, HT29, was used to generate 3D spheroids. HT29 
has been used extensively in 3D cell culturing based studies, and from previous multiple studies, we have found 
HT29 to form spheroidal cultures with relative  ease45–48. As demonstrated in Figs. 2A and 8, we found the micro-
fluidic platform presented here, enables HT29 cells to form uniformly sized spheroidal structures. 3D spheroids 
grew to a maximum of around 250 μm in diameter, dictated by the diameters of the spheroid-culturing wells. 
Typically, HT29 3D spheroids with ≥ 300 μm diameters, possess hypoxic and necrotic cores with physiological 
gradients of cell proliferation (outer rapidly proliferating and inner non-proliferating cells)49. It could therefore 
be postulated, that the HT29 3D spheroids grown in this study did not possess the in vivo like physiological 
gradients or hypoxic/necrotic cores.
Our device was additionally designed to streamline high-throughput chemosensitivity experiments and 
improve the overall efficiency of 3D cell culturing. To demonstrate this, we used the chemotherapeutic agent, 
5-Fluorouracil, to treat the HT29 spheroids. As 5-FU is currently the primary anti-cancer drug used to treat 
colorectal  cancers50, it makes for an excellent model system and demonstrates the relevant real-world application 
of our device. Following the culturing of 3D spheroids, treatment and analysis could be performed conveniently 
on-chip, through the perfusion of anti-cancer drugs and other culture media. Fluorescent imaging (qualitative 
Figure 3.  3D cell culturing wells in the PDMS flow chips. The concave shaped wells in the PDMS flow chips 
were designed to assist in the aggregation of cells following the deposit of HT29 cells in suspension. On Day 0 
cells would be added to the wells forming cell aggregates which would then be cultured under static conditions 
for another 2 days to form 3D spheroids. Fluid flow would then be applied through the wells following the 
formation of 3D spheroids.
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analysis) using propidium iodide to visually highlight cell death in spheroids was complimented by the leak-
age and quantification of LDH in the supernatant (quantitative analysis), an indicator of cell death. Our study 
Figure 4.  Culturing spheroids in the microfluidic flow chip. (A) HT29 cells were prepared in cell suspension 
and seeded into the spheroid culturing wells of the PDMS chips and cultured under static conditions in the 
PDMS chips. Transillumination microscopic images of 3D spheroids were taken showing the progressive 
development of 3D HT29 spheroids at Days 0, 2, 4 and 7. Scalebar = 400 μm. (B) HT29 cells in suspension 
were seeded onto the PDMS flow chips and cultured under static conditions for 10 days. Spheroid volume 
measurements were taken at Days 0, 2, 4, 7 and 10 to show the progressive growth of spheroids over time in the 
microfluidic devices. Data represents means with standard deviation of 3 independent experiments (3 spheroids 
per experiment). (C) 3D HT29 spheroids were cultured under static conditions in the PDMS flow chips for 
10 days. Spheroids were subjected to ethanol gradient dehydration and coated with 4 nm of iridium and then 
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makes use of a single 3D cell culturing microfluidic platform, to administer an anti-cancer treatment and permit 
subsequent on-chip viability imaging confirmed by an LDH assay.
In our study, we demonstrated two different setups for performing chemosensitivity experiments in the 
microfluidic devices. The first utilised a single syringe pump to drive flow through one device at a time (Fig. 5). 
This limited-perfusion setup permits simple experiments to be conducted with a single experimental endpoint. 
However, experiments can also be performed with continuous flow as demonstrated by the second setup utilising 
a multichannel pump (Fig. 6). An advantage of continuous flow setup is that it better models the physiological 
flow of systemic circulation in the body. This second setup also enables multiple devices to be run simultaneously 
in parallel. Each channel is controlled independently, therefore flow through one microfluidic device can be 
switched off without disrupting flow through the rest of the channels or devices. In addition, the continuous flow 
setup was designed to be placed into a conventional tissue culturing incubator, permitting prolonged experiments 
(lasting multiple days) to be performed using existing laboratory infrastructure and environmental standards.
conclusion
In this study, we have developed and evaluated a 3D cell culturing microfluidic device. The device comprises 
a layer of PDMS with concave 3D cell culturing wells sandwiched between two layers of transparent PMMA, 
allowing for direct visualization. HT29 colorectal cancer cells in suspension were seeded into the wells through 
the central port on the top PMMA layer and subsequently formed into 3D spheroids. These spheroids were 
Figure 5.  Culturing, treating and evaluating anti-cancer activity in spheroids through limited-perfusion 
microfluidic flow. (A) Photographic image and (B) schematic diagram of the limited-perfusion microfluidic 
setup using a single syringe pump. A fluid filled syringe is placed into the pump which is connected to an 
adjustable 3-way flow valve. The valves are connected to microfluidic devices and through to universal tubes 
for the collection of supernatants. During fluid flow the 3-way valve is open. Once complete perfusion through 
microfluidic devices has occurred the pump is stopped, and the 3-way valve is closed to create a vacuum and 
statically hold fluids in the microfluidic devices. HT29 cells in suspension were seeded and cultured under static 
conditions in the microfluidic devices flow chip for 2 days to form 3D spheroids. 3D spheroids were then treated 
with 5-Fluorouracil (5-FU, 500 µM) under fluid flow for 25 min at 20 µL/min and then incubated for 24 h under 
static conditions. (C) The supernatant was then collected through fluid flow and plated into 96-well plates and 
the Lactate dehydrogenase (LDH) assay was performed. Data are shown relative to control treated cultures 
and represent means with standard deviation of 3 independent experiments (3 replicates per experiment). 
(D) Spheroids were also stained with Hoechst 33342 (Blue) and propidium iodide (Red) fluorescent dyes 
through flow and fluorescently imaged. Scalebar = 200 μm. Images are representative of at least 3 independent 
experiments. (E) Hoechst 33342 and propidium iodide fluorescent intensity from 3D HT29 spheroids was 
digitally quantified using ImageJ. Data represents means with standard deviation of 3 independent experiments 
(3 spheroids per experiment).
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treated through one-time or continuous perfusion of the anti-cancer drug, 5-Fluorouracil, and the resulting cell 
viability was analysed using fluorescent microscopy and an LDH assay. The two perfusion regimes simulated dif-
ferent physiological flow conditions and enabled the evaluation of distinct methods of administering anti-cancer 
treatment. Finally, the microfluidic device described here offers a convenient, efficient and quick platform for 
generating, culturing, treating and analysing 3D cancer spheroids and will facilitate high-throughput screening 
of anti-cancer drugs on complex 3D in vitro models.
Methods
Designing and fabricating the microfluidic devices. A single microfluidic device consists of a central 
PDMS chip consisting of a single straight flow channel joining the inlet to outlet, with an array of 3D cell cultur-
ing wells located towards the centre. This is sandwiched between two layers of transparent PMMA allowing for 
direct optimal imaging. Schematic designs for the different parts of the flow device were drawn in SolidWorks 
(Dassault Systèmes, Vélizy-Villacoublay, France). To create the PDMS flow chips, the inverse design was printed 
as a reusable master mould on an EnvisionTEC 3D printer (EnvisionTEC GmbH, Gladbeck, Germany) in a pho-
tocurable acrylonitrile butadiene styrene (ABS) thermoplastic polymer. The well-forming hemispherical “pim-
Figure 6.  Time course monitoring of chemosensitivity in spheroids through continuous microfluidic flow. (A) 
Photographic image and (B) schematic diagram of the continuous perfusion microfluidic setup using peristaltic 
pump. Fluid filled syringes were connected to the peristaltic pump that was connected to the microfluidic 
devices and through to universal tubes for the collection of supernatants. HT29 cells in suspension were seeded 
and cultured under static conditions in the microfluidic devices flow chip for 2 days to form 3D spheroids. 
Spheroids were then treated with 5-FU (200 μM) through continuous perfusion at 20 µL/min for 0, 1, 2, 3 
and 5 days. The independent channel controllable pump allowed flow through devices to be independently 
controlled permitting flow to stop through one device without influencing flow through other devices. (C) The 
supernatant was collected at the different time-points through fluid flow and plated into 96-well plates and the 
Lactate dehydrogenase (LDH) assay was performed. Data are shown relative to cell media control and represent 
means with standard deviation of 3 independent experiments (3 replicates per experiment). (D) Spheroids 
were also stained with Hoechst 33342 (Blue) and propidium iodide (Red) fluorescent dyes through flow and 
fluorescently imaged. Scalebar = 100 μm. Images are representative of at least 3 independent experiments. (E) 
Hoechst 33342 and propidium iodide fluorescent intensity from 3D HT29 spheroids was digitally quantified 
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ples” in the master mould are 250 µm in diameter located in 5 × 5 array, on a pitch of 500 µm × 500 µm (Fig. 7). 
Chips were then cast from the master mould using PDMS with a release agent to aid removal. The PDMS flow 
chips were fixed between two layers of PMMA. The top layer of PMMA was fabricated with fluid inlet and outlet 
ports and a cell seeding port in the centre, while the bottom layer of PMMA serves as the device base (Fig. 1). 
The PMMA layers were machined from cast sheet, with inlet and outlet ports positioned to match the ends of the 
PDMS chip and machined to take standard UNF 1/4-28 flangeless fittings. An additional port was machined into 
the top layer of PMMA, located directly above the 3D cell culturing wells. The microfluidic device was fashioned 
together using four bolts, one in each corner, to hold the assembly together. Inlet and outlet ports were con-
nected to tubing using flangeless fittings and a blanking plug was fitted to the central port to allow direct access 
to the cell culturing wells (Fig. 1). Following assembly, the microfluidic device was sterilised using a steam and 
high-pressured autoclave prior to the addition of cells.
Preparation of cancer cells. The human colorectal adenocarcinoma cell line, HT29, was obtained from 
the European Collection of Authenticated Cell Cultures (Salisbury, UK). Cells were cultured in Roswell Park 
Memorial Institute (RPMI) 1640 Medium plus GlutaMAX (Gibco by Life Technologies, Paisley, UK) (without 
sodium pyruvate) supplemented with 10% (v/v) Fetal Bovine Serum (FBS) (Sigma-Aldrich) and maintained 
at 37 °C, 5%  CO2 and 95% relative humidity (RH). Cell cultures were passaged weekly and seeded into 75 cm2 
tissue culture flasks (Corning Inc., New York, USA). Complete cell media was changed once per week. 80–90% 
confluent cell cultures were used for the experiments.
Culturing 3D tumour spheroids in a microfluidic device. Cells were washed and trypsinised to cre-
ate a cell suspension of 2 × 107 cells/mL in cell medium. 20 μL of cell suspension was deposited into the wells 
of assembled PDMS chips. The chips were then incubated and maintained under static conditions at 37 °C/5% 
 CO2/95% RH. All cell media was changed daily using a pipette. Manual cell counting and acquisition of the 
images of spheroids was performed using the EVOS FL Imaging System (Life Technologies). For scanning elec-
tron microscopy (SEM), spheroids were cultured for 10 days then briefly washed with DPBS, fixed in 2.5% (v/v) 
glutaraldehyde for 20 min and subjected to increasing gradients of ethanol dehydration (25%, 40%, 60%, 80%, 
90% and 100%). The top surface of the PDMS flow chip was then coated with 4 nm of iridium and imaged using 
a FEI Nova NanoSEM450 scanning electron microscope (Thermo Fisher).
Anti-cancer treatment of 3D tumour spheroids in microfluidic devices. Culturing 3D HT29 sphe‑
roids. HT29 cells in suspension were deposited through the central port of the top PMMA layer into the wells 
of the PDMS flow chip in an assembled microfluidic device. Cell media was then flowed through the micro-
fluidic device at 10  µL/min using an Aladdin Single-Syringe Pump (AL-2000, World Precision Instruments, 
Florida, USA). Following complete cell media perfusion through the device, the device was incubated (37 °C/5% 
 CO2/95% RH) under static conditions.
Figure 7.  The mould used to cast the PDMS flow chips. (A) PDMS chips were created by casting using a mould 
that was 3D printed using photocurable acrylonitrile butadiene styrene with the inverse designs of the PDMS 
chips and (B) 3D cell culturing wells (250 µm in diameter) located in the middle of the mould in a 5 × 5 array 
on a pitch of 500 µm x 500 µm. (C) The layered printing to make the mould resulted in ‘step-like’ convex shaped 
mounds for the 3D cell culturing wells.
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5‑FU treatment (Limited‑perfusion conditions). Two different flow conditions were used to study chemosensi-
tivity in 3D HT29 spheroids. For the first (limited-perfusion) condition, 48 h after seeding cells, 500 µM 5-FU 
was prepared in cell media and perfused through the microfluidic device at 20 µL/min using the single-syringe 
pump. This approach can only accommodate one device at a time. Following the perfusion of 500 µL of 5-FU 
(20 µL/min) completely through the microfluidic device, lasting 25 min, flow was stopped and the device was 
detached from the pump and placed back into incubation (37 °C/5%  CO2/95% RH). The spheroids were incu-
bated with 5-FU under static conditions for an additional 24 h.
5‑FU treatment (Continuous perfusion conditions). For the second (continuous perfusion) condition, 48 h after 
seeding cells, 250 µM 5-FU was prepared in cell media and perfused continuously through five microfluidic 
devices in parallel at 20 µL/min for 5 days. An Ismatec IPC Low-Speed Digital Peristaltic Pump (Cole-Parmer 
Instrument Company Ltd, St. Neots, UK) with 8 independent channels, was used to drive continuous fluid flow. 
Microfluidic devices under continuous perfusion were kept in incubation (37 °C/5%  CO2/95% RH) for the dura-
tion of the experiments.
Evaluating cytotoxicity in 3D tumour spheroids. Lactate dehydrogenase (LDH) assay. Spent cell 
culture media supernatant was collected from the microfluidic device and stored at − 20  °C until the end of 
the continuous flow 5-FU treatment period. The LDH cytotoxicity assay was performed using the Pierce LDH 
Cytotoxicity Assay Kit (Thermo Fisher) and carried out as per the manufacturer’s instructions and guidelines. 
This method has been previously applied to evaluate the cell viability of tumour tissue specimens cultured on a 
microfluidic  platform51–53.
Fluorescent imaging. 5 μg/mL Hoechst 33342 and 1.3 μg/mL Propidium Iodide was prepared in cell media, 
and flowed into the device at 20 µL/min. Spheroids were incubated with the dyes for 30 min, washed with DPBS 
Figure 8.  Uniform sized 3D HT29 spheroids were formed in the microfluidic device. (A) Transillumination 
microscopic image and (B) spheroid diameter measurements of HT29 cells in suspension that were seeded onto 
the PDMS flow chips and cultured under static conditions for 7 days forming uniform sized spheroids. Data 
shown represent means with standard deviation of 3 independent experiments (3 replicates per experiment). 
Images are representative of at least 3 independent experiments.
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through flow and imaged using the EVOS FL Imaging System (Life Technologies). Imaging was carried out 
directly on-chip. We note that the spheroids were relatively well held in the individual wells. This is ideal when 
moving between different laboratory and measurement platforms.
image and statistical analysis. ImageJ (National Institute of Health, Maryland, USA) was used to analyse 
the transillumination and fluorescent images of 3D spheroids. The student t-test and one-way ANOVA were 
used to perform data statistical analyses using GraphPad Prism 8 (GraphPad Software, Inc., California, USA). 
p < 0.05 was considered to be statistically significant. Data is presented as the mean ± standard deviation.
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